Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 10/20 | 0.69 |
| ▸ | TUBB4A | P04350 | 9/20 | 0.69 |
| ▸ | TUBB | P07437 | 9/20 | 0.69 |
| ▸ | TUBA3C | P0DPH7 | 9/20 | 0.69 |
| ▸ | TUBA1B | P68363 | 9/20 | 0.69 |
| ▸ | TUBA4A | P68366 | 9/20 | 0.69 |
| ▸ | TUBB4B | P68371 | 9/20 | 0.69 |
| ▸ | TUBB3 | Q13509 | 9/20 | 0.69 |
| ▸ | TUBB2A | Q13885 | 9/20 | 0.69 |
| ▸ | TUBB8 | Q3ZCM7 | 9/20 | 0.69 |
| ▸ | TUBA3E | Q6PEY2 | 9/20 | 0.69 |
| ▸ | TUBA1A | Q71U36 | 9/20 | 0.69 |
| ▸ | TUBA1C | Q9BQE3 | 9/20 | 0.69 |
| ▸ | TUBB6 | Q9BUF5 | 9/20 | 0.69 |
| ▸ | TUBB2B | Q9BVA1 | 9/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136491 | 1.00 | TUBB1 (0.69) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29136488 | 1.00 | TUBB1 (0.69) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL9243542 | 0.87 | TUBB1 (0.75) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL9243558 | 0.87 | TUBB1 (0.75) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17938788 | 0.85 | TUBB1 (0.63) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27835441 | 0.85 | TUBB1 (0.63) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17938785 | 0.85 | TUBB1 (0.63) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27723385 | 0.85 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL27835357 | 0.85 | TUBB1 (0.63) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL235883 | 0.84 | NFE2L2 (0.75) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-117222406-A | Compounds for the treatment and prophylaxis of covd-19 | T·塞凯赖什 | 2023-12-12 | — | — | CN | claimed |
| US-20230141224-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC | 2023-05-11 | — | — | US | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| CN-114796470-A | Resveratrol compound and CAR-T cell targeting NKG2D ligand combined preparation of medicine for treating malignant tumor | 深圳宾德生物技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2021202032-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC (US) | 2021-10-07 | — | — | WO | claimed |
| WO-2018210880-A1 | STILBENES FOR PRE-HARVEST TREATMENT AND CROP PROTECTION | EVOLVA SA (CH) | 2018-11-22 | — | — | WO | claimed |
| WO-2018210872-A1 | STILBENES FOR POST-HARVEST TREATMENT AND FOOD PRESERVATION AND/OR SHELF LIFE EXTENSION | EVOLVA SA (CH) | 2018-11-22 | — | — | WO | claimed |
| US-20160215306-A1 | METHOD FOR PRODUCING MODIFIED RESVERATROL | EVOLVA SA (CH) | 2016-07-28 | — | — | US | claimed |
| EP-3039132-A2 | A METHOD FOR PRODUCING MODIFIED RESVERATROL | Evolva SA (CH) | 2016-07-06 | — | — | EP | claimed |
| WO-2009001046-A2 | [11C]METHOXY-RADIOLABELLED 2,3',4,5'-TETRAMETHYLSTILBENE (TMS) AND ITS PREPARATION AND USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-31 | — | — | WO | claimed |
| EP-1450819-A4 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | UNIV CALIFORNIA (US) | 2008-01-23 | — | — | EP | claimed |
| CN-1729007-A | Compositions and methods for preventing and treating inflammatory diseases, autoimmune diseases, and transplant rejection | UNIV CALIFORNIA (US) | 2006-02-01 | — | — | CN | claimed |
| US-20040242500-A1 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-02 | — | — | US | claimed |
| EP-1450819-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | The Regents of the University of California (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003039557-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-05-15 | — | — | WO | claimed |
| EP-1045853-A4 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | UNIV ARIZONA STATE (US) | 2002-04-17 | — | — | EP | claimed |
| JP-2002500227-A | — | — | 2002-01-08 | — | — | JP | claimed |
| WO-2001021165-A1 | RESVERATROL ANALOGS FOR PREVENTION OF DISEASE | RUTGERS, THE STATE UNIVERSITY (US) | 2001-03-29 | — | — | WO | claimed |
| EP-1045853-A1 | SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY (US) | 2000-10-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242500-A1 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | TNF, HLA-DRB1, IL5 | TUBB1 1374/4885TUBB4A 1463/4885TUBB 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.